Comparative Pharmacology
Head-to-head clinical analysis: FOLLISTIM versus MENOPUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLLISTIM versus MENOPUR.
FOLLISTIM vs MENOPUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
None Documented
None Documented
The terminal elimination half-life ranges from 16 to 24 hours (mean ~19 hours) following subcutaneous administration. In patients with renal impairment, half-life may be prolonged, necessitating dose adjustment.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Primarily renal; approximately 70% of the dose is excreted unchanged in urine. A minor fraction (less than 5%) appears in feces via biliary elimination. The remainder is metabolized via hepatic pathways to inactive metabolites.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Gonadotropin
Gonadotropin